Weikang Bio-Technology Group Co., Inc. is principally engaged in developing, manufacturing and distributing Traditional Chinese Medicine (TCM), and health and nutritional supplements in China, in compliance with requisite Chinese licenses and approvals. The Company is also expanding its business scope to develop, manufacture and distribute Chinese herbal extract products and GMP certified western prescription and OTC pharmaceuticals through its acquisition of Tianfang. For more information, please visit http://www.weikangbio.com
The Indian stock market indices continued their downward trend due to a rise in food inflation above 18%. Cement and fertilizer stocks declined significantly. The government deferred removing subsidies for urea. The Sensex closed down 116 points and the Nifty fell 32 points. VIX volatility increased while sectoral gains were seen in IT and infrastructure stocks.
How to Develop a PowerPoint Pitch Deck for Biotech Investor PresentationsCraig Shimasaki
A critical tool for all biotech entrepreneurs is an Investor Slide Deck or “Pitch” Deck. This example is provided to help those who want guidance on what topics and information are important for a biotech investor presentation. I have put together some basic information about what a biotech investor pitch deck should contain when presenting for the first time to a group of potential investors. Realize that this is not a template per se in which to simply fill in the blanks, but an ordered list of topics that are significant to most all biotechnology investors. For more information read the BioBlog at www.biosourceconsulting.com
Presentation by Steve Scott, Lorna Neilson, Mary Canady, and David Welch at the San Diego Biotechnology Network's Bootstrapping Biotech event October 29th 2009.
Conclusive Proof that L&L International (LLEN) Does Not Own the Ping Yi MineGeoInvesting LLC
In a red flag alert issued to our premium members Friday, January 13th, 2012, we presented a Chinese SAIC filing and multiple website links showing that the Ping Yi Mine that allegedly represents 37% of LLEN’s production capacity is owned not by LLEN, but by an investment group of four Chinese nationals led by Mr. Hu Shiwei, and that this group is currently offering the mine for sale in China.
New Energy Systems Group is a vertically integrated original design manufacturer and distributor of lithium ion batteries and backup power systems for mobile phones, laptops, digital cameras, MP3s and a variety of other portable electronics. The company's end-user consumer products are sold under the Anytone brand in China, and the company has begun expanding its international sales efforts. The fast pace of new mobile device introductions in China combined with a growing middle class make it fertile ground for New Energy's end-user consumer products as well as its high-powered, lightweight lithium ion batteries. In addition to historically strong organic growth, New Energy anticipates that it will benefit from economies of scale, broader distribution, greater production capacity and higher profit margins in 2010. Additional information about the company is available at: http://www.newenergysystemsgroup.com .
EquityNet Research was formed in January 1999 to provide the investing public with professional, independent, objective research on under-followed public companies. This report follows Biostar Pharmaceuticals (OTCBB:BSPM) and was published Feb 17, 2010
China MediaExpress Investor Day Conference, Sept. 7, 2010GeoInvesting LLC
CME operates the largest television advertising network on inter-city express buses in China. CME generates revenue by selling advertisements on its network of television displays installed on express buses originating in nine of China’s regions, including the four municipalities of Beijing, Shanghai, Tianjin and Chongqing and five provinces, namely Guangdong, Jiangsu, Fujian, Sichuan and Hebei.
The Indian stock market indices continued their downward trend due to a rise in food inflation above 18%. Cement and fertilizer stocks declined significantly. The government deferred removing subsidies for urea. The Sensex closed down 116 points and the Nifty fell 32 points. VIX volatility increased while sectoral gains were seen in IT and infrastructure stocks.
How to Develop a PowerPoint Pitch Deck for Biotech Investor PresentationsCraig Shimasaki
A critical tool for all biotech entrepreneurs is an Investor Slide Deck or “Pitch” Deck. This example is provided to help those who want guidance on what topics and information are important for a biotech investor presentation. I have put together some basic information about what a biotech investor pitch deck should contain when presenting for the first time to a group of potential investors. Realize that this is not a template per se in which to simply fill in the blanks, but an ordered list of topics that are significant to most all biotechnology investors. For more information read the BioBlog at www.biosourceconsulting.com
Presentation by Steve Scott, Lorna Neilson, Mary Canady, and David Welch at the San Diego Biotechnology Network's Bootstrapping Biotech event October 29th 2009.
Conclusive Proof that L&L International (LLEN) Does Not Own the Ping Yi MineGeoInvesting LLC
In a red flag alert issued to our premium members Friday, January 13th, 2012, we presented a Chinese SAIC filing and multiple website links showing that the Ping Yi Mine that allegedly represents 37% of LLEN’s production capacity is owned not by LLEN, but by an investment group of four Chinese nationals led by Mr. Hu Shiwei, and that this group is currently offering the mine for sale in China.
New Energy Systems Group is a vertically integrated original design manufacturer and distributor of lithium ion batteries and backup power systems for mobile phones, laptops, digital cameras, MP3s and a variety of other portable electronics. The company's end-user consumer products are sold under the Anytone brand in China, and the company has begun expanding its international sales efforts. The fast pace of new mobile device introductions in China combined with a growing middle class make it fertile ground for New Energy's end-user consumer products as well as its high-powered, lightweight lithium ion batteries. In addition to historically strong organic growth, New Energy anticipates that it will benefit from economies of scale, broader distribution, greater production capacity and higher profit margins in 2010. Additional information about the company is available at: http://www.newenergysystemsgroup.com .
EquityNet Research was formed in January 1999 to provide the investing public with professional, independent, objective research on under-followed public companies. This report follows Biostar Pharmaceuticals (OTCBB:BSPM) and was published Feb 17, 2010
China MediaExpress Investor Day Conference, Sept. 7, 2010GeoInvesting LLC
CME operates the largest television advertising network on inter-city express buses in China. CME generates revenue by selling advertisements on its network of television displays installed on express buses originating in nine of China’s regions, including the four municipalities of Beijing, Shanghai, Tianjin and Chongqing and five provinces, namely Guangdong, Jiangsu, Fujian, Sichuan and Hebei.
Company Description - AIVtech International Group Co. (“AIVtech” or the “Company”) is a leading manufacturer of consumer electronics
products, such as furniture audio and multimedia speakers in China. The Company plans to capitalize on its strong domestic position
to become a well-known international brand. AIVtech focuses on the integration of electronic devices, such as multimedia speakers, with
furniture and has coined the term “electronic furniture” to describe its products. The Company’s brand—AIV—stands for “Audio & Interactive
Video” and describes the integration of audio and video to provide complete audio-visual systems for its customers. Currently, the
Company classifies its products within three categories: (1) casual furniture audio such as rocking chair speakers and video game chairs;
(2) hi-fi digital and multimedia speakers; and (3) LCD/LED televisions, which entered into production in April 2010. The Company was
founded in October 2004 and is headquartered in Shenzhen, China, and its manufacturing facility is located in Dongguan.
Share Transfer from Putai to Ming Zhao (September 2009)GeoInvesting LLC
This document outlines corporate changes for a company including registration of new shareholders Ming Zhao (99%) and Wei Zhang (1%), amendments to the articles of association, and three share transfer agreements where 90% of shares were transferred from Putai to Ming Zhao, 9% from Yao Zhao to Ming Zhao, and 1% from Yao Zhao to Wei Zhang according to notes on pages 5-10 of the document.
Vocus cloud marketing software analyst day presentation june 6 2012GeoInvesting LLC
- Vocus provides cloud marketing software to help businesses attract, engage and retain customers.
- Digital marketing represents a significant opportunity, with the market expected to grow to $77 billion by 2016.
- Vocus' software suite addresses key functions of modern digital marketing like social, search, email and publicity.
- The company has a scalable and profitable business model focused on the SMB market of $3,000-30,000 customers.
Share Pledge from Putai Mining to Citic Trust (Jan, 2011)GeoInvesting LLC
This document contains registration materials for a share pledge agreement between CITIC Trust and Putai, where Putai pledged its 51% stake in Shanxi Coal to CITIC Trust as collateral for a RMB 5,022.5 million loan. The document includes a share pledge registration book cover, index, application, shareholder lists for Shanxi Coal and Puda Mining, a credit confirmation agreement between CITIC Trust and Putai, the share pledge agreement, minutes from a Puda Mining shareholder meeting approving the pledge, and business licenses for the involved companies.
This investor presentation provides an overview of the company including its corporate profile and financials from 2006-2009. It highlights the company's investment in organic dairy farming and processing in China along with management details and 5-year projections for growth through 2012. The presentation concludes with the company's strategy to pursue a public listing.
Opexa therapeutics corporate presentation september 2016OpexaTherapeutics
Opexa Therapeutics presented information on their precision immunotherapy platform and lead programs. Their lead asset, Tcelna, is in Phase 2b development for secondary progressive multiple sclerosis and top-line data is expected in the next 1-2 months. They are also developing OPX-212 for neuromyelitis optica, an orphan indication with no approved therapies. Opexa has secured an option agreement with Merck Serono for Tcelna in MS and could receive up to $25 million in milestones if Merck exercises their option after seeing Phase 2b data.
Wiekang Biotech Investor Presentation, June 2010GeoInvesting LLC
Weikang Bio-Technology Group Co., Inc. is principally engaged in developing, manufacturing and distributing Traditional Chinese Medicine (TCM), and health and nutritional supplements in China, in compliance with requisite Chinese licenses and approvals. The Company is also expanding its business scope to develop, manufacture and distribute Chinese herbal extract products and GMP certified western prescription and OTC pharmaceuticals through its acquisition of Tianfang. For more information, please visit http://www.weikangbio.com
This document provides writing prompts for journal entries, assignments, and a writer's notebook focused on literary arts. The prompts explore topics like memories, opinions, problems, knowledge, interests, and writing goals. They also include prompts for descriptive and reflective writing exercises utilizing techniques like point of view, dialogue, character development, and poetry.
China Ruitai is engaged in the production, sales, and exportation of specialty chemicals, with a primary focus on non-ionic cellulose ether products. Cellulose ether is an organic chemical that dissolves in water and other organic solvents. Due to the surface-active properties of cellulose ether, it acts as a thickener and stabilizer in aqueous solutions, making it a beneficial additive in a wide variety of commercial industries and products, including, but not limited to the pharmaceutical industry, the construction industry, PVC products, food and beverage products, petroleum, and cosmetics. Specific examples of applications in which cellulose ether products are used include: as a stabilizer and thickener in latex paint; in mortar dry mix for building materials; to improve the performance of resin in PVC production; as a membrane reagent, stabilizer, and thickener in pharmaceuticals; and to improve jam, ice cream, toothpaste and lipsticks in the food and cosmetic industries. TaiAn is one of the largest non-ionic cellulose ether producers in China.
Part of the MaRS BioEntrepreneurship series:
http://www.marsdd.com/bioent
Speaker: Roman Masley, Managing Director, SHI Capital
Topics Addressed:
* Do’s and don’ts in biotech fundraising
* The importance of the pitch
* Formulating a strategic funding plan that encompasses all financing opportunities
* Understanding the angel investor and what type of investment they are looking for
* Knowing the key issues, pitfalls, and hot buttons when approaching venture capitalist
* Matching the company's needs with the appropriate types of funding opportunities.
* Exploring strategic financing alternatives such as monetizing royalty streams, risk-sharing structure financings, PIPEs and collaborations.
* Understanding venture debt and when it is best used in financing a startup.
GALE-401 is a proprietary controlled release formulation of anagrelide being developed for the treatment of essential thrombocythemia (ET) as a potential third line therapy. Phase 1 and 2 clinical trials showed that GALE-401 maintains platelet lowering effects while reducing peak plasma concentrations and adverse events compared to immediate release anagrelide. The company plans to initiate a Phase 3 trial in Q2 2017 to further evaluate GALE-401 in ET patients who are intolerant or refractory to first and second line therapies such as hydroxyurea and anagrelide.
- The document outlines Oncolytics Biotech's corporate presentation from September 2016. It discusses the company's oncolytic virus REOLYSIN, its two mechanisms of action, positive clinical trial data showing increased progression-free and overall survival for certain patient groups, evidence of tumor responses including reductions in liver metastases, an upcoming colorectal cancer study, potential in multiple myeloma based on preclinical data, commercial-scale manufacturing, and a strong intellectual property portfolio with over 400 issued patents worldwide. The presentation positions REOLYSIN as a promising cancer therapeutic prepared for late-stage clinical trials.
This document provides an overview of venture capital and private equity, including:
1. Venture capital refers to equity investments made for launching or expanding businesses, while private equity provides funding to non-public companies.
2. Growing companies often need external financing for activities like product development, market expansion, and maintaining liquidity until cash flow turns positive.
3. Acquiring venture capital involves investors thoroughly assessing business plans and management teams before potentially providing funding after 3-4 years of due diligence.
Venture capital power point presentationKarthik S Raj
Venture capital involves investing in startup companies and small businesses with growth potential. It provides funding to new companies and helps them grow. Venture capital is high-risk but can provide high returns. It is typically invested in technology, biotech, or other innovative companies. Venture capital funds pool money from investors and then invest in ventures on their behalf. They provide capital as well as management assistance to the companies they invest in.
The document provides guidance on developing an effective 12-slide pitch deck to attract investors. It outlines the key slides to include such as an introduction, problem statement, market opportunity, team, solution, customers, go-to-market strategy, competition, financials, milestones, and summary. The presentation should tell a compelling story that shows the problem being solved, market size, solution, team qualifications, business model, and path to success in order to pique the investor's interest. Presenters are advised to practice their pitch and be prepared to discuss the business knowledgeably.
The document summarizes the history and growth of SEOmoz, an SEO software company founded in 2001 by Rand Fishkin and his mother Gillian. It details how SEOmoz grew from a small consultancy into a profitable software company with over 10,000 subscribers. The document outlines SEOmoz's plans to raise $20-25 million in funding to expand its product suite, team, and marketing in order to serve a wider audience and become the leading software for organic marketers. The goal is for SEOmoz to become Seattle's next billion dollar company.
The document provides an overview of Tianyin Pharmaceutical Inc. (TPI), a Chinese pharmaceutical company listed on the NYSE AMEX exchange. It summarizes TPI's financial performance from 2003-2012, describing its revenue growth from $0.4M to $69.6M, expanding product portfolio from 7 to 58 products, and increasing employees from 80 to 1,200 over that period. The document also outlines TPI's manufacturing facilities, sales and marketing network, product portfolio, management team, and future plans to relocate facilities and focus on higher-margin specialty products.
Danish pharmaceutical company Novo Nordisk (founded in 1923) is a global leader in diabetes care with 52% of the insulin market share. As of November 2008, it had a market capitalization of $33 billion. Novo Nordisk focuses on diabetes care, haemostatic agents, hormone replacement, growth disorders, obesity, and inflammation therapies. It has a strong pipeline of new drugs for diabetes care, including two new insulins due in early 2009. The company aims to increase its market share in diabetes care and expand into related areas like obesity and inflammatory diseases.
Nestlé is expanding into the healthcare field through its new division, Nestlé Health Science. The presentation discusses opportunities in healthcare given trends of aging populations and increasing chronic diseases. It introduces Nestlé Health Science's vision to provide personalized nutrition solutions for medical conditions. Currently, Nestlé has a healthcare nutrition business and is expanding its scientific platforms and diagnostic capabilities through acquisitions to build a transformational healthcare business over the next 5 years.
wyeth J.P. Morgan 26th Annual Healthcare Conferencefinance12
This document summarizes a presentation given at the J.P. Morgan 26th Annual Healthcare Conference. It discusses Wyeth's financial performance in Q3 and the first nine months of 2007, with revenue and earnings growth across key franchises like Enbrel, Effexor, Prevnar, and Protonix. It also highlights Wyeth's approved, pending, and upcoming opportunities, including new data on drugs like Pristiq, Torisel, and expanded indications for Prevnar 13. Wyeth expects continued growth from these pharmaceutical products and advancing its oncology pipeline.
Company Description - AIVtech International Group Co. (“AIVtech” or the “Company”) is a leading manufacturer of consumer electronics
products, such as furniture audio and multimedia speakers in China. The Company plans to capitalize on its strong domestic position
to become a well-known international brand. AIVtech focuses on the integration of electronic devices, such as multimedia speakers, with
furniture and has coined the term “electronic furniture” to describe its products. The Company’s brand—AIV—stands for “Audio & Interactive
Video” and describes the integration of audio and video to provide complete audio-visual systems for its customers. Currently, the
Company classifies its products within three categories: (1) casual furniture audio such as rocking chair speakers and video game chairs;
(2) hi-fi digital and multimedia speakers; and (3) LCD/LED televisions, which entered into production in April 2010. The Company was
founded in October 2004 and is headquartered in Shenzhen, China, and its manufacturing facility is located in Dongguan.
Share Transfer from Putai to Ming Zhao (September 2009)GeoInvesting LLC
This document outlines corporate changes for a company including registration of new shareholders Ming Zhao (99%) and Wei Zhang (1%), amendments to the articles of association, and three share transfer agreements where 90% of shares were transferred from Putai to Ming Zhao, 9% from Yao Zhao to Ming Zhao, and 1% from Yao Zhao to Wei Zhang according to notes on pages 5-10 of the document.
Vocus cloud marketing software analyst day presentation june 6 2012GeoInvesting LLC
- Vocus provides cloud marketing software to help businesses attract, engage and retain customers.
- Digital marketing represents a significant opportunity, with the market expected to grow to $77 billion by 2016.
- Vocus' software suite addresses key functions of modern digital marketing like social, search, email and publicity.
- The company has a scalable and profitable business model focused on the SMB market of $3,000-30,000 customers.
Share Pledge from Putai Mining to Citic Trust (Jan, 2011)GeoInvesting LLC
This document contains registration materials for a share pledge agreement between CITIC Trust and Putai, where Putai pledged its 51% stake in Shanxi Coal to CITIC Trust as collateral for a RMB 5,022.5 million loan. The document includes a share pledge registration book cover, index, application, shareholder lists for Shanxi Coal and Puda Mining, a credit confirmation agreement between CITIC Trust and Putai, the share pledge agreement, minutes from a Puda Mining shareholder meeting approving the pledge, and business licenses for the involved companies.
This investor presentation provides an overview of the company including its corporate profile and financials from 2006-2009. It highlights the company's investment in organic dairy farming and processing in China along with management details and 5-year projections for growth through 2012. The presentation concludes with the company's strategy to pursue a public listing.
Opexa therapeutics corporate presentation september 2016OpexaTherapeutics
Opexa Therapeutics presented information on their precision immunotherapy platform and lead programs. Their lead asset, Tcelna, is in Phase 2b development for secondary progressive multiple sclerosis and top-line data is expected in the next 1-2 months. They are also developing OPX-212 for neuromyelitis optica, an orphan indication with no approved therapies. Opexa has secured an option agreement with Merck Serono for Tcelna in MS and could receive up to $25 million in milestones if Merck exercises their option after seeing Phase 2b data.
Wiekang Biotech Investor Presentation, June 2010GeoInvesting LLC
Weikang Bio-Technology Group Co., Inc. is principally engaged in developing, manufacturing and distributing Traditional Chinese Medicine (TCM), and health and nutritional supplements in China, in compliance with requisite Chinese licenses and approvals. The Company is also expanding its business scope to develop, manufacture and distribute Chinese herbal extract products and GMP certified western prescription and OTC pharmaceuticals through its acquisition of Tianfang. For more information, please visit http://www.weikangbio.com
This document provides writing prompts for journal entries, assignments, and a writer's notebook focused on literary arts. The prompts explore topics like memories, opinions, problems, knowledge, interests, and writing goals. They also include prompts for descriptive and reflective writing exercises utilizing techniques like point of view, dialogue, character development, and poetry.
China Ruitai is engaged in the production, sales, and exportation of specialty chemicals, with a primary focus on non-ionic cellulose ether products. Cellulose ether is an organic chemical that dissolves in water and other organic solvents. Due to the surface-active properties of cellulose ether, it acts as a thickener and stabilizer in aqueous solutions, making it a beneficial additive in a wide variety of commercial industries and products, including, but not limited to the pharmaceutical industry, the construction industry, PVC products, food and beverage products, petroleum, and cosmetics. Specific examples of applications in which cellulose ether products are used include: as a stabilizer and thickener in latex paint; in mortar dry mix for building materials; to improve the performance of resin in PVC production; as a membrane reagent, stabilizer, and thickener in pharmaceuticals; and to improve jam, ice cream, toothpaste and lipsticks in the food and cosmetic industries. TaiAn is one of the largest non-ionic cellulose ether producers in China.
Part of the MaRS BioEntrepreneurship series:
http://www.marsdd.com/bioent
Speaker: Roman Masley, Managing Director, SHI Capital
Topics Addressed:
* Do’s and don’ts in biotech fundraising
* The importance of the pitch
* Formulating a strategic funding plan that encompasses all financing opportunities
* Understanding the angel investor and what type of investment they are looking for
* Knowing the key issues, pitfalls, and hot buttons when approaching venture capitalist
* Matching the company's needs with the appropriate types of funding opportunities.
* Exploring strategic financing alternatives such as monetizing royalty streams, risk-sharing structure financings, PIPEs and collaborations.
* Understanding venture debt and when it is best used in financing a startup.
GALE-401 is a proprietary controlled release formulation of anagrelide being developed for the treatment of essential thrombocythemia (ET) as a potential third line therapy. Phase 1 and 2 clinical trials showed that GALE-401 maintains platelet lowering effects while reducing peak plasma concentrations and adverse events compared to immediate release anagrelide. The company plans to initiate a Phase 3 trial in Q2 2017 to further evaluate GALE-401 in ET patients who are intolerant or refractory to first and second line therapies such as hydroxyurea and anagrelide.
- The document outlines Oncolytics Biotech's corporate presentation from September 2016. It discusses the company's oncolytic virus REOLYSIN, its two mechanisms of action, positive clinical trial data showing increased progression-free and overall survival for certain patient groups, evidence of tumor responses including reductions in liver metastases, an upcoming colorectal cancer study, potential in multiple myeloma based on preclinical data, commercial-scale manufacturing, and a strong intellectual property portfolio with over 400 issued patents worldwide. The presentation positions REOLYSIN as a promising cancer therapeutic prepared for late-stage clinical trials.
This document provides an overview of venture capital and private equity, including:
1. Venture capital refers to equity investments made for launching or expanding businesses, while private equity provides funding to non-public companies.
2. Growing companies often need external financing for activities like product development, market expansion, and maintaining liquidity until cash flow turns positive.
3. Acquiring venture capital involves investors thoroughly assessing business plans and management teams before potentially providing funding after 3-4 years of due diligence.
Venture capital power point presentationKarthik S Raj
Venture capital involves investing in startup companies and small businesses with growth potential. It provides funding to new companies and helps them grow. Venture capital is high-risk but can provide high returns. It is typically invested in technology, biotech, or other innovative companies. Venture capital funds pool money from investors and then invest in ventures on their behalf. They provide capital as well as management assistance to the companies they invest in.
The document provides guidance on developing an effective 12-slide pitch deck to attract investors. It outlines the key slides to include such as an introduction, problem statement, market opportunity, team, solution, customers, go-to-market strategy, competition, financials, milestones, and summary. The presentation should tell a compelling story that shows the problem being solved, market size, solution, team qualifications, business model, and path to success in order to pique the investor's interest. Presenters are advised to practice their pitch and be prepared to discuss the business knowledgeably.
The document summarizes the history and growth of SEOmoz, an SEO software company founded in 2001 by Rand Fishkin and his mother Gillian. It details how SEOmoz grew from a small consultancy into a profitable software company with over 10,000 subscribers. The document outlines SEOmoz's plans to raise $20-25 million in funding to expand its product suite, team, and marketing in order to serve a wider audience and become the leading software for organic marketers. The goal is for SEOmoz to become Seattle's next billion dollar company.
The document provides an overview of Tianyin Pharmaceutical Inc. (TPI), a Chinese pharmaceutical company listed on the NYSE AMEX exchange. It summarizes TPI's financial performance from 2003-2012, describing its revenue growth from $0.4M to $69.6M, expanding product portfolio from 7 to 58 products, and increasing employees from 80 to 1,200 over that period. The document also outlines TPI's manufacturing facilities, sales and marketing network, product portfolio, management team, and future plans to relocate facilities and focus on higher-margin specialty products.
Danish pharmaceutical company Novo Nordisk (founded in 1923) is a global leader in diabetes care with 52% of the insulin market share. As of November 2008, it had a market capitalization of $33 billion. Novo Nordisk focuses on diabetes care, haemostatic agents, hormone replacement, growth disorders, obesity, and inflammation therapies. It has a strong pipeline of new drugs for diabetes care, including two new insulins due in early 2009. The company aims to increase its market share in diabetes care and expand into related areas like obesity and inflammatory diseases.
Nestlé is expanding into the healthcare field through its new division, Nestlé Health Science. The presentation discusses opportunities in healthcare given trends of aging populations and increasing chronic diseases. It introduces Nestlé Health Science's vision to provide personalized nutrition solutions for medical conditions. Currently, Nestlé has a healthcare nutrition business and is expanding its scientific platforms and diagnostic capabilities through acquisitions to build a transformational healthcare business over the next 5 years.
wyeth J.P. Morgan 26th Annual Healthcare Conferencefinance12
This document summarizes a presentation given at the J.P. Morgan 26th Annual Healthcare Conference. It discusses Wyeth's financial performance in Q3 and the first nine months of 2007, with revenue and earnings growth across key franchises like Enbrel, Effexor, Prevnar, and Protonix. It also highlights Wyeth's approved, pending, and upcoming opportunities, including new data on drugs like Pristiq, Torisel, and expanded indications for Prevnar 13. Wyeth expects continued growth from these pharmaceutical products and advancing its oncology pipeline.
Dr Yongsheng Wang, General Manager, Jinyu BiopharmaceuticalsKisaco Research
Dr. Yongsheng Wang is the Vice President of Jinyu Bio-Technology Co. Ltd. and General Manager of Jinyu Baoling Bio-pharma Co. Ltd. He discussed the animal health market in China, highlighting key growth drivers such as increasing livestock and poultry output. The animal health market is growing over 10% annually, driven by demand for high quality vaccines and products for private farms. Jinyu Bio-Technology is a leading animal vaccine company in China with a 12% market share, focusing on innovative vaccines and technology.
This document provides an agenda and key highlights from Sanofi's Q1 2019 results presentation:
- The presentation reviews Sanofi's Q1 2019 financial results, with sales increasing 4.2% and EPS growth of 9.4% driven by launches and diminishing LoEs in the US.
- Several business units saw double-digit growth including Genzyme, Vaccines, and China/Emerging Markets, partially offset by lower sales of Diabetes and Established Products.
- The pipeline highlights potential approvals over the next year including Dupixent in additional indications and geographies as well as Zynquista and Cemiplimab.
using innovation in tobacco - prakit vathesatogkitNCAS1
The document proposes establishing a Thai Health Promotion Fund to support health promotion activities outside of the Ministry of Health (MOH). The new approach would focus on lifestyle and environmental factors to promote population health, rather than only providing services to the sick. The fund would receive 2% of alcohol and tobacco tax revenues annually to support a more sustainable and predictable budget for health promotion programs led by various government agencies and non-profits. Key provisions and regulations would ensure transparency and accountability for use of the funds.
01 Future of the Global Pharma Industry.pdfAarthi358332
The document discusses key trends in the global pharmaceutical industry. It finds that the industry has grown tremendously over the last century, with global pharmaceutical sales now exceeding $1 trillion annually. The industry is projected to continue growing significantly, with the global market tripling in size by 2060. The largest growth is expected in China, with its market increasing four-fold to rival the size of the US market. The document also examines four innovation trends that will impact the industry: improved peptide manufacturing methods, controlling inflammation's role in disease, expanding use of nucleic acid therapeutics, and development of implantable devices for drug delivery and disease monitoring.
Abbott laboratories pakistan (pvt) limitedFaraz Mehdi
This document provides an overview of Abbott Laboratories, a global healthcare company operating in over 130 countries. It discusses Abbott's vision, core values, product lines including pharmaceuticals, nutritionals, diagnostics and diabetes care. The document also includes Abbott Pakistan's background, SWOT analysis, financial performance from 2009-2006, and how profits were allocated in 2009. It states Abbott Pakistan is committed to continuing as a going concern with over Rs. 4.9 billion in assets in 2009.
Catalent is the global leader in drug development and manufacturing. It has over 1,300 patents and is well-positioned to benefit from substantial industry growth of 6-10% annually through 2020. While pricing pressures could slow industry growth, Catalent's business model focusing on development, delivery, and supply solutions provides long-term stable revenues. The recommendation is to buy Catalent stock, which trades at $29.13 but has a target price of $35.99 based on discounted cash flow analysis.
China Health Labs is a leading provider of total lab solutions and diagnostic equipment and reagents in China. It has four business units focused on rural hospitals, military and emergency services, food safety labs, and large urban hospitals. The company has experienced strong revenue growth in recent years and has a large addressable market supported by Chinese government policies. It has proprietary technology, partnerships with government agencies, and a strategy focused on expanding into new geographic areas and developing new solutions.
Biocon - Key updates and events
1. Biopharma posts robust revenue growth: 15% YoY
2. Statins: Strong growth in Q2; robust sales of Simvastatin and Pravastatin
3. Focus on improving operational efficiencies to augment capacities
4. Our biosimilar co-marketing Insulins partner, Pfizer has launched in the Indian markets.
The document is an investor presentation for Biostar Pharmaceuticals, Inc. that outlines the company's business model, financial performance, growth opportunities, and priorities for 2011. Some key points:
- Biostar has a vertically integrated business model that includes R&D, raw material production, manufacturing, and distribution.
- The company has experienced strong revenue and profit growth in recent years and expects 20-25% revenue growth in 2011.
- Biostar's flagship product is Xin Aoxing, an OTC drug for hepatitis B that generated over $53 million in sales in 2010.
- Growth opportunities include increasing market share in China and other Asian countries for Xin Aoxing, as
1) The document discusses trends and opportunities for rice bran oil (RBO) consumption in China and globally. It notes that while RBO is a premium healthy oil, its consumption remains low due to historical, technological, and perception barriers.
2) To increase RBO consumption, Wilmar has demonstrated a case study of its efforts in China since 2010 to promote RBO through various marketing channels and over 200 million consumer outreach activities.
3) The document concludes by discussing ongoing opportunities to increase RBO consumption through electronic commerce/e-commerce and expanding world trade of RBO.
1) The document discusses trends and opportunities for rice bran oil (RBO) consumption in China and globally. It notes that while RBO is a premium healthy oil, its consumption remains low due to historical, technological, and perception barriers.
2) To increase RBO consumption, Wilmar has demonstrated a case study of its work in China over the past decade to develop higher quality RBO products and promote their health benefits through various marketing channels to consumers.
3) Going forward, the document identifies opportunities to further increase RBO consumption through electronic commerce/e-commerce and expanding exports and world trade.
The company founder effectively life-hacked a $billion dollar OTC product and was awarded 6 patents for it. The funds raised were to prove efficacy and will probably be the only funding required before licensing.
We took a highly technical breifing and created a story that is both understandable and informative. We developed the brands, strategy, copy, graphics, and put together the deck and arranged key meetings with investors.
www.wildoutwest.com
wyeth Download Documentation Credit Suisse Group Healthcare Conferencefinance12
This document is a presentation by Michael Kamarck from Wyeth discussing the company's manufacturing capabilities and strategies. It summarizes that Wyeth has a diversified business across pharmaceuticals, biotechnology, vaccines, and other areas. It has made over $3.5 billion in investments to support its biomanufacturing network and developed platform technologies to standardize processes. This allows production of multiple pipeline and commercial products using consistent materials and equipment. Wyeth has demonstrated the ability to increase yields and capacity for products like Enbrel and Prevnar through technological advances.
wyeth Credit Suisse Group Healthcare Conferencefinance12
This document provides an overview of Wyeth's business, including its diversification across scientific platforms, business platforms, and therapeutic approaches. It discusses Wyeth's core biotech/vaccine franchises that have high growth potential, such as Enbrel and Prevnar. The document also summarizes Wyeth's investments in biomanufacturing infrastructure and its leadership in biotech manufacturing and process development. Wyeth's standardized technology platforms are highlighted as helping to improve existing products and drive efficiencies.
The document discusses Pfizer's plans to create the world's premier biopharmaceutical company through acquiring Wyeth. The acquisition will strengthen Pfizer's leadership in key areas like biologics and vaccines, expand its portfolio of growth drivers, and enhance its scientific and manufacturing capabilities. It analyzes how the acquisition advances Pfizer's strategic objectives such as becoming a leader in biologics, entering the vaccines market, and expanding in emerging markets. Charts show how the combined company will have a more diversified portfolio of therapies and platforms.
This document outlines Pfizer's plans to acquire Wyeth to create the world's premier biopharmaceutical company. The acquisition will diversify Pfizer's portfolio and strengthen its leadership in key therapeutic areas and geographies. Pfizer expects the deal to advance its strategic priorities and deliver $2 billion in cost savings by 2011 on top of $4 billion in synergies from the transaction. The all-cash-and-stock deal is valued at $68 billion and will be funded through cash, debt, and Pfizer stock.
Similar to Wiekang Biotech Investor Presentation, June 2010 (20)
GeoInvesting has a longstanding reputation as short sellers. Our work in exposing more than $10 billion in U.S. listed China based frauds was featured in the recent feature documentary The China Hustle. We also offer portfolio protection for our members, based on the research strategies that have made us extremely well-known for our on the ground due diligence.
There are multiple niches in the microcap space where GeoInvesting’s track record has proven that consistent alpha can be achieved. Each strategy provides favorable percentage returns, but is limited in size. A combination of well-defined strategies can enhance portfolio returns by offering the benefit of diversifying into uncrowded situations with low market correlation without overexposing to a single stock.
We believe the best way for a company of your size to approach a microcap strategy would be to deploy a target capital amount across a few basket portfolios of around 5 stocks each. These baskets can vary by strategy and time horizon. Around these baskets, we can implement one-off ideas as they emerge based on very high probability special situations
The document summarizes the investment strategies and approach of Geoinvesting.com, which focuses on identifying undervalued microcap stocks. Some of their main strategies include buying stocks that are underreacting to good news ("Buy on Pullback"), targeting companies that may be acquisition candidates, and investing in turnaround situations. They provide several case studies of past investments that achieved significant returns, such as NV5 Global, GTT Communications, Zynex, and Vocus, to illustrate how they successfully implemented these strategies.
Dr. Andrew W. Lo - Adaptive Markets: Financial Evolution and the Speed of Tho...GeoInvesting LLC
This document summarizes Andrew Lo's presentation on adaptive markets. Lo discusses how the traditional view of efficient markets based on rational investor behavior is incomplete. He argues markets are adaptive, influenced by human psychology and constantly changing environments. Lo presents his adaptive markets hypothesis, drawing on evolutionary biology and noting markets evolve as individuals compete and learn. This new view has implications for investing, regulation, and developing more sophisticated indexes that account for individual investor needs and behaviors.
The document discusses the benefits of exercise for mental health. Regular physical activity can help reduce anxiety and depression and improve mood and cognitive functioning. Exercise causes chemical changes in the brain that may help protect against mental illness and improve symptoms.
Pioneer Power Solutions (PPSI) May 2017 Investor PresentationGeoInvesting LLC
Pioneer Power Solutions, Inc. (PPSI) manufactures, sells and services a broad range of electrical transmission, distribution and on-site power generation equipment in the field of utility, industrial, commercial original equipment manufacturer, and in critical power markets.
This presentation covers:
Transmission and Distribution Solutions - Equipment that distributes, controls, conditions and monitors the flow of electrical energy while protecting critical equipment such as transformers, motors, data center equipment and other machinery.
Critical Power Solutions - Onsite power generation systems, control equipment and services that ensure uninterrupted power to operations in times of emergency and in primary power applications, including data centers
Maj Soueidan Oct 2016 Traders For A Cause PresentationGeoInvesting LLC
Maj Soueidan is the founder of GeoInvesting.com, which helps everyday investors find underfollowed micro-cap stock ideas through information arbitrage. GeoInvesting educates investors, saves them time performing research, and aims to provide institutional-quality ideas. Maj takes advantage of readily available information not found by others to identify inflection points in stocks before they are processed by the broader market. While some of Maj's past ideas have increased over 1,000%, others that were once multi-baggers are now down substantially. GeoInvesting presents elevator pitches on ideas, issues daily reports, and keeps members alerted through social media.
Maj Soueidan Oct 2016 Microcap Conference Philly PresentationGeoInvesting LLC
Inflection points can serve as triggers for you to invest in particular stocks right before the meat of their growth cycles or at a time when they’ve improved their risk profiles for various reasons. I’ve found that the identification of inflection points has helped me pinpoint companies that tend to become acquisition targets. Of over 40 stocks that have been both the focus of our research AND acquired, some of these acquisitions were actually predicted by my team; others were just a byproduct of what happens when good research is rewarded.
Shedding Light on Tech Pro Technology (03823.HK)GeoInvesting LLC
• Tech Pro is a company that seems to be suffering from an identity crisis
• We believe the stock price is detached from the reality of our on the ground due diligence and the company’s financials
• Our due diligence raises questions that we believe should be brought to the attention of both the company’s auditor and regulators
• We believe the company will require continued dilutive equity financing to sustain operations
• We are currently short Tech Pro (03823.HK)
One of key strategies I use to find microcap diamonds in the rough is to combine the concepts of Growth + Value. On April 11, 2016, I presented (videos at bottom) at the 2016 Microcap Conference Toronto, where I gave a speech on this very subject. More detail on this presentation can be seen at my blog, http://geoinvesting.com/combining-tenets-growth-value-find-hidden-microcap-opportunities/.
President and Co-Founder of GeoInvesting presented at the 2016 Microcap Conference in Toronto, focusing on stock trading and investing strategies revolving around using a combination of growth and value when selecting investments.
microcapconf.com/conferences/toronto-2016/
April 11, 2016 - Heng Ren White Paper on Chinese BuyoutsGeoInvesting LLC
- 38 Chinese companies have announced management buyouts of US shareholders since 2015, offering below-average premiums. On average, premiums were less than three-quarters of the US average.
- These companies significantly increased their cash holdings after listing in the US, from an average of $46M pre-IPO to $280M at the time of buyout announcements. However, they are squeezing out US investors at prices below fair value and sometimes even below the IPO price.
- After buying out US shareholders, some companies have offered shares in China at much higher values, indicating the buyout offers to US investors were too low and unfairly enriched company management. Regulators need to close loopholes to
Moseda Technologies Company Presentation, November 2015GeoInvesting LLC
Moseda Technologies Inc. primarily engages in the development and operation of mobile device management software systems that allow the management to tracking of assets using mobile devices. It develops SmartCare, a mobile health solution for accessing, tracking, and managing patient health records securely from the Web, smartphone, or tablet; for automatic vital tracking; and for healthcare providers to manage staff and tasks. The company also provides SmartCare@Home, a telemedicine solution that utilizes the mobile, wearables, and SaaS technology to allow for remote patient monitoring. In addition, it offers SmartFleet, a fleet and asset tracking software for businesses that operate mobile and vehicle fleets. The company is headquartered in Vancouver, Canada.
Moseda Technologies Inc. primarily engages in the development and operation of mobile device management software systems that allow the management to tracking of assets using mobile devices. It develops SmartCare, a mobile health solution for accessing, tracking, and managing patient health records securely from the Web, smartphone, or tablet; for automatic vital tracking; and for healthcare providers to manage staff and tasks. The company also provides SmartCare@Home, a telemedicine solution that utilizes the mobile, wearables, and SaaS technology to allow for remote patient monitoring. In addition, it offers SmartFleet, a fleet and asset tracking software for businesses that operate mobile and vehicle fleets. The company is headquartered in Vancouver, Canada.
This CEO will present Phase 2 clinical trial results on November 7th that could revolutionize Alzheimer's treatment. If the results continue the promising early Phase 2A results of 83% of patients benefiting and a 4x improvement in memory over current drugs, the small company's stock could experience unprecedented gains as high as 2,150% as it moves towards Phase 3 trials. The discovery of an effective treatment for Alzheimer's, which currently has no cure, could be worth $67 billion annually and save the US healthcare system from being overwhelmed by rising Alzheimer's costs in the coming decades.
The document summarizes several stock picks and trades made by GeoInvesting between February and April 2015:
- They traded in and out of AMCN based on news and an investment valuing the stock at $8.
- They added to their position in ESCC at $0.40 in March 2015 based on an imminent liability resolution announced in April, causing the stock to rise 100%.
- In April they stated ORBK's muted reaction to strong earnings was a buying opportunity but visibility may only extend a few quarters.
- Several other trades and recommendations over this period included TOUR, HOFT, GBSN, NNBR, NVEE, ISDR, MNTX, BIOQ, LAS
L & L Energy's (LLEN) Dickson Lee Sentencing Memorandum - 2015GeoInvesting LLC
This document is a government sentencing memo recommending a 60 month prison sentence for Dickson Lee, the founder and CEO of coal company L&L Energy. It summarizes that Lee pled guilty to securities fraud for fabricating the existence of a CFO and lying on SEC filings to fraudulently obtain a NASDAQ listing, which boosted the company's stock price. It also claims that later, with the company desperate for cash, Lee secretly issued and dumped over 500,000 shares on the market without disclosure. The memo argues the fraud was severe and undermined market integrity, and that the sentencing guidelines fail to capture the full severity of Lee's actions.
We have reason to believe that the SEC already has Qihoo on its radar. Given the information presented in this report, along with other issues that we have omitted, we believe that Qihoo will be delisted from the NYSE and management charged with securities fraud.
Equity Insights - Sionex (SINX) Research Report May 2012GeoInvesting LLC
Sionix designs, develops, markets, and sells water management and treatment
solutions intended for use in the oil and gas, agriculture, disaster relief, and
municipal (both potable and wastewater) markets. The Company’s Mobile
Water Treatment System (“MWTS”) is configured dependent upon customer
requirements and integrates components and technologies based on those
requirements. Within these systems, the company utilizes a Dissolved Air
Floatation (“DAF”) system with patented technology that management
estimates removes more than 99.95 percent of the organic, and most
inorganic, particles in water. This includes the removal of hydrocarbons,
insoluble metals, infectious bacteria, algae, and color. Historically, DAF systems
similar to the DAF used in Sionix MWTS created bubbles that were 50 microns
or greater, which were unable to remove all contaminants due to their size.
The Sionix technology utilizes and refines DAF technology to provide a pretreatment
process using ambient oxygen and minimal chemical flocculent
aids that can be more efficient and cost-effective. The company’s patented
technology makes micro-bubbles that allow a much greater percentage of
contaminants to be captured, floated to the surface, and skimmed off with
minimal use of chemicals. The Company’s MWTS is mobile and modular such
that it can be transported easily to address a wide range of water treatment
markets and can meet customers’ needs for new systems or to replace or
integrate with existing filtration technologies. Sionix was initially incorporated
in Utah in 1996 and reincorporated in Nevada in 2003. The company’s website
is www.sionix.com.
The document is a presentation from Neenah Paper, Inc. given at an investor conference in February 2012. It provides an overview of Neenah Paper, including:
1) Neenah Paper leads in performance-based technical products and high-end printing papers. It has two business segments: Technical Products and Fine Paper.
2) The company has successfully transformed its business mix and financial performance through strategic acquisitions and focus on specialty markets.
3) Neenah Paper has continued strong financial momentum, with top and bottom line growth, improving margins, and increasing return on capital. A recent acquisition is expected to further drive growth and value creation.
In a tight labour market, job-seekers gain bargaining power and leverage it into greater job quality—at least, that’s the conventional wisdom.
Michael, LMIC Economist, presented findings that reveal a weakened relationship between labour market tightness and job quality indicators following the pandemic. Labour market tightness coincided with growth in real wages for only a portion of workers: those in low-wage jobs requiring little education. Several factors—including labour market composition, worker and employer behaviour, and labour market practices—have contributed to the absence of worker benefits. These will be investigated further in future work.
1. Elemental Economics - Introduction to mining.pdfNeal Brewster
After this first you should: Understand the nature of mining; have an awareness of the industry’s boundaries, corporate structure and size; appreciation the complex motivations and objectives of the industries’ various participants; know how mineral reserves are defined and estimated, and how they evolve over time.
BONKMILLON Unleashes Its Bonkers Potential on Solana.pdfcoingabbar
Introducing BONKMILLON - The Most Bonkers Meme Coin Yet
Let's be real for a second – the world of meme coins can feel like a bit of a circus at times. Every other day, there's a new token promising to take you "to the moon" or offering some groundbreaking utility that'll change the game forever. But how many of them actually deliver on that hype?
2. Elemental Economics - Mineral demand.pdfNeal Brewster
After this second you should be able to: Explain the main determinants of demand for any mineral product, and their relative importance; recognise and explain how demand for any product is likely to change with economic activity; recognise and explain the roles of technology and relative prices in influencing demand; be able to explain the differences between the rates of growth of demand for different products.
Economic Risk Factor Update: June 2024 [SlideShare]Commonwealth
May’s reports showed signs of continued economic growth, said Sam Millette, director, fixed income, in his latest Economic Risk Factor Update.
For more market updates, subscribe to The Independent Market Observer at https://blog.commonwealth.com/independent-market-observer.
Lecture slide titled Fraud Risk Mitigation, Webinar Lecture Delivered at the Society for West African Internal Audit Practitioners (SWAIAP) on Wednesday, November 8, 2023.
5 Tips for Creating Standard Financial ReportsEasyReports
Well-crafted financial reports serve as vital tools for decision-making and transparency within an organization. By following the undermentioned tips, you can create standardized financial reports that effectively communicate your company's financial health and performance to stakeholders.
Understanding how timely GST payments influence a lender's decision to approve loans, this topic explores the correlation between GST compliance and creditworthiness. It highlights how consistent GST payments can enhance a business's financial credibility, potentially leading to higher chances of loan approval.
Solution Manual For Financial Accounting, 8th Canadian Edition 2024, by Libby...Donc Test
Solution Manual For Financial Accounting, 8th Canadian Edition 2024, by Libby, Hodge, Verified Chapters 1 - 13, Complete Newest Version Solution Manual For Financial Accounting, 8th Canadian Edition by Libby, Hodge, Verified Chapters 1 - 13, Complete Newest Version Solution Manual For Financial Accounting 8th Canadian Edition Pdf Chapters Download Stuvia Solution Manual For Financial Accounting 8th Canadian Edition Ebook Download Stuvia Solution Manual For Financial Accounting 8th Canadian Edition Pdf Solution Manual For Financial Accounting 8th Canadian Edition Pdf Download Stuvia Financial Accounting 8th Canadian Edition Pdf Chapters Download Stuvia Financial Accounting 8th Canadian Edition Ebook Download Stuvia Financial Accounting 8th Canadian Edition Pdf Financial Accounting 8th Canadian Edition Pdf Download Stuvia
2. Safe Harbor Statement
In accordance with the 1995 Securities Litigation Reform Act of the "exemption"
meaning, this statement documents contain "forward-looking statements". This
statement related to understand and unknown risks, uncertainties and other
factors will cause the company’s statement not match by the results, in which
including sales and regional economic conditions and competitive conditions,
customer relation Changes, access to capital, the difficulty of promoting new
products, existing products market conditions, customers for the existing and
new product awareness and other factors. Relevantly, the company believed that
the results is reasonable in this forward-looking statements , but can not
guarantee that the forecast entirely correct. There is no duty that company to
update the forward-looking information contained in this statements.
2
3. Company Overview
Weikang Bio-Technology Group is a leading developer,
Weikang Bio-Technology Group is a leading developer,
manufacturer and marketer of
manufacturer and marketer of
Traditional Chinese Medicine (TCM)
Traditional Chinese Medicine (TCM)
Western prescription and OTC pharmaceuticals
Western prescription and OTC pharmaceuticals
Other health and nutritional products
Other health and nutritional products
It has two subsidiaries:
Heilongjiang WeiKang
Chinese herbal-based health and
nutritional supplements and therapeutics
Brand name "Rongrun"
Founded in 2005
210 employees
Guizhou TianFang
Develops, manufactures and distributes
Chinese herbal extract products and GMP
certified western drugs
300 employees
Acquired in 2008, founded in 1998 3
5. Investment Highlights
Rapid revenue and net income growth
Expanding portfolio of high margin, original SFDA
approved products
Strong R&D capability and investment ensure a strong
pipeline - targeting launching 2-3 new products a year
GMP-certified manufacturing lines scalable up to $107
million in annual production
Acquisition strategy enhances growth opportunity
Managed by pharmaceutical industry experts
Attractive valuation
5
6. Attractive Industry Dynamics
China’s pharmaceutical market is currently the 5th largest in the world
Expected to grow to the 2nd largest by 2020 and the largest by 2050
Medical expenditure ranks the 3rd after food and education*
Government stimulus package expands New Rural Cooperative Medical
System
Investing USD $124 billion (2009-2011) with earmarks to improve
insurance coverage
Building 30,000 township hospitals and 700,000 village clinics with
estimated annual increase in supply purchase of 42% from these over
the next 5 years
Fragmented industry, dominated by local enterprises, creates opportunity
for consolidation
Approximately 70% of the market supply is
provided by small, local pharmaceutical companies**
*DOH Survey, 12/2/2004
**Economy Watch
6
7. Preventative Healthcare
Preventative medicine is the primary source of medical care for 700
million rural Chinese who cannot afford adequate healthcare*
Patients generally have to pay 50% - 60% of healthcare expense out-of-
pocket
Out-of-pocket healthcare expenditures increased from 25% in 1990 to
58% in 2006**
Middle class consumers risk spending all of life savings on medical
expenses
Private health insurance uncommon
Preventative care will remain important as universal coverage to be
implemented in 2011 will only cover basic medical services
The best doctor treats the problem before
The best doctor treats the problem before
the problem becomes the disease ~~
the problem becomes the disease
* factsanddetails.com, April 2010
** China’s Ministry of Health Old Chinese medical proverb
Old Chinese medical proverb
8. Weikang’s Target Market
Consumers 60 years old and above
Approximately 170 million Chinese over 60 years old
Aging population regularly takes supplements to
improve health condition
Population with regular / chronic health problems
70% of the population estimated to have some degree of health
problems
Increasing health problems associated with modern industrial life
including diseases related to stress and obesity
Consumers interested in preventative health care
8
9. High Margin Portfolio
TianFang
Product portfolio of Western medicine and TCM
Eight products in the market
Seven SFDA approved drugs
Average gross margin 48.5%
Two SFDA approved product expected to be launched Q3 and Q4
WeiKang
Product portfolio of TCM
Seven SFDA approved nutrient medicines on the market
Seven SFDA approved product expected to be launched Q3 and Q4
Three drugs in pipeline
Average gross margin 66.1%
WeiKang,
28.13%
Tiangfang,
71.87%
% Sales by subsidiaries (2009)
9
10. TianFang’s Product Portfolio
% of 2009 Gross
Product Main Function
Revenue Margin
Ferrous Fumarate
Treats iron deficiency anemia 24.24% 51.28-54.39%
Granule
Eucommia
Nourishes the liver and kidney
Ulmoides Oliv 23.26% 46.25-49.03%
Strengthens muscles and bones
Granule
Tinidazole Vaginal
Effervescent Tablet Treats bacterial infections in the female
14.87% 39.76-43.55%
reproductive system
Nourishes the liver and kidney
Bushen Qiangshen
Enriches yin, strengthens yang 7.85% 63.37%
Tablet
Enhances health and brain function
Intended to treat duodenal ulcers, gastric
Ranitidine
ulcer, reflux esophagitis, Zollinger-Ellison
Hydrochloride 1.66% 11.24%
syndrome, and other symptoms with gastric
Capsules
acid overproduction
10
11. WeiKang’s Product Portfolio
% of 2009 Gross
Product Main Function
Revenue Margin
Promotes the restoration of the natural
Rongrun Youth
balance of female hormones during 3.78% 66.55%
Keeping Capsules menopause
Reduces free radicals and oxidative stress
Rongrun Energy
Intended to reduce the risk of 3.75% 66.55%
Keeping Capsules cardiovascular disease
Reduces the onset of cardiovascular
Rongrun Vitamin Sugar disease and fatigue for diabetics 4.11% 64.43%
Capsules Promotes healthy aging
Lowers blood lipid levels in order to reduce
Rongrun Intestine the likelihood of brain and heart vessel
related diseases 3.84% 66.55%
Cleansing Capsules
Strengthens immune system
Reduces cholesterol level in arteries
Rongrun Artery
Promotes healthier heart and brain 3.95% 65.74%
Cleansing Capsules functions
Rongrun Royal Jelly Immuno-regulatory
4.63% 61.73%
Extract anti-cancer properties
Rongrun Kidney Boost
Strengthen and promotes a healthy kidney 4.06% 71.93%
Tonic
11
12. Strong Pipeline
Ten drugs in various stages of approval from the SFDA
Top R&D projects include
Has anti-cancer properties and is used in the treatment of radiation
10-HDA sickness and angiocardiopathy
Received SFDA approval and expected to launch in 3Q 2010
ShuangBaoGu ( a Provides several health benefits including the prevention and treatment of
variety of mushroom cardiovascular disease
grown on a salty land) Production expected to begin by end of 2010
Used to treat atrial fibrillation (irregular heartbeats)
Dofetilide
Approved for clinical test
Develop therapeutic properties of glycyrrhize acid
Licorice Flavonoid Treated conditions and afflictions includes allergies, hepatitis,
Project inflammation and swelling, including peptic ulcers hypertension, excessive
potassium in the body, skin conditions, viral infections, tumor formation
and cancer, specifically breast cancer, weight loss
KangYuan A herbal based medicine effective in treating depression
Antidepressant Has passed several stages of testing and ready for clinical trials
Capsules Estimated R&D expenditure $71,000
12
13. Extensive Distribution Network
Total sales network covers almost the whole country via two modes of
distribution: exclusive distributors and wholesale drug trading firms
WeiKang’s products are sold in five provinces and Beijing
through six distributors
TianFang’s products are sold nationwide through over 60
dedicated sales agents, based in 33 cities
Integrating TianFang’s distribution channels and logistics with
WeiKang to achieve synergy and economies of scale
Plans to build a national logistic chain system for medicine distribution
by 2012
13
14. Sales and Distribution
Distribution channels:
Clinical, through doctors and hospitals mostly prescription and
OTC drugs
Retail pharmacies, mostly OTC drugs
Supermarkets, food and nutrition stores, mostly TCM based
therapeutics
Third party sales outlets, such as rural medical centers
Conference sales and Internet orders
WaiKang plans to expand the distribution to 3 northeast provinces
and to south and southwest provinces
Consolidate and share the channels for both WeiKang and TianFang
products
Open bidding for new dealerships
from potential distributors
14
15. Sales and Marketing Strategies
Direct mail pamphlets to seniors
Includes consultation information
Emails to younger and busy urban residents
Provides information on company products and web based ordering
platform
Free delivery services in northern cities during winter season
Strong brand name advertising for TianFang OTC drugs
Partnership with wholesalers
Regular promotions
Product information forums
Incentive schemes
Plans for future acquisitions that can
expand sales channels
15
16. Production Facilities
WeiKang has six production lines
TianFang has three production lines
Highest quality equipment with national GMP certification
Unique technology synthesizes raw materials
Ensures quality and effectiveness of therapeutics
Helps reduce costs and enhance gross margins
Scalable production lines
Up to USD $107 million of potential annual production capacity
WeiKang & Tianfang production rate at 35% & 50% of total
capacity, respectively
Production capabilities
Capsule Oral liquid
Granules Gel and soft paste
Tablets Powder
16
17. R&D Capabilities
Dr. Zhengbin Xu, M.D head of R&D
Over 40 years of clinical and research experience in TCM
Published 56 articles in international and domestic journals
Professional affiliations with
The China Medicine Research Institute
Heilongjiang Chinese Medicine Co., Ltd.
The Chinese Medical Association
R&D team composed of 16 industry experts
Received 4 national awards
Advanced R&D done in collaboration with Northeastern Forestry
University and Tianjin University
Two drug testing facilities
Shuangcheng, 246 Sq Meters, GMP compliant
Guizhou TianFang, GMP certified
17
18. Growth Strategy
Organic
Committed to R&D of new products and improving existing product
portfolio to secure and expand market share
Diversify vertically into growing herbal and other raw materials to
secure supply and lower cost
Increase spending for advertising and continue building brand
Acquisition
Target companies that broaden product portfolio and expands
distribution network
TianFang acquisition expanded distribution network nationwide
Expand and improve product portfolio with TCM,
WM, therapeutics and nutraceuticals
18
19. Experienced Management Team
Yi Wang – CEO and Chairman, Founder
Weikang CEO since 2002
Physician of over 30 years with extensive clinical experience and bio-medical research
experience
Served as Director of Harbin Geriatric Hospital and Harbin Chinese Medical Hospital
MBA from Beijing University
Master in Medical Science, Harbin Medical University
Yanhua Liu – CFO
CFO of WeiKang since July, 2005 and a China CPA
20 years of experience of Finance and Accounting
Bachelor in Finance, Heilongjiang Agricultural and Mechanical College
Zhengbin Xu – Chief Technology Officer
CTO of Weikang since July 2007
40 years of clinical and research experience on Traditional Chinese Medicine and Nutrition
Publish 56 research papers on international and domestic journals
Graduate of Northwest University of China.
Vice President of China Medical Association.
Bing Wei - Chief Marketing Director
Joined in Weikang in 2005
Bachelor’s degree from Harbin Commerce University
19
22. Increasing Net Income
$18 80.0%
$15.64
56.6%
$12 39.0% 40.0%
32.9% 38.1%
$7.30
$5.45
$6 $3.85 0.0%
-$0.45
$0 -40.0%
2007 2008 2009 3 months 2009 3 months 2010
-54.7%
-$6 -80.0%
$m
Net Income Profit Margin
22
23. Balance Sheet Highlights
USD in millions Dec. 31 2009 Mar. 31 2010
Cash and Equivalents $11.4 $18.1
Current Assets 11.7 19.5
Current Liabilities 10.5 10.8
Long-Term Debt 0.0 0.0
Shareholder's Equity 23.4 31.1
23
24. Attractive Valuation
Ticker Price Market Cap Revenues Net Income Y/Y Net Y/Y PE
Company
(Exch) (6/8/10) (mm) 2009 (mm) 2009 (mm) Income % revenue % (TTM)
Weikang Bio- WKBT
$2.79 $76.45 $47.4 $15.6 116.67% 270.31% 4.5
Technology (OTCBB)
Biostar BSPM
$3.23 $83.42 $53.3 $10.5 56.95% 57.24% 9.8
Pharmaceuticals (OTCBB)
Renhuang RHGP
$2.00 $74.47 $43.4 $14.8 43.69% 3.67% 4.7
Pharmaceutical (OTCBB)
American Oriental AOB
$2.72 $213.18 $296.1 $41.4 -13.39% 11.90% 5.1
Bioengineering (NYSE)
CSKI
China SkyOne Medical $11.33 $190.23 $130.1 $34.4 19.40% 41.72% 5.5
(NASDAQ)
Tianyin Pharmaceutical TPI
$2.67 $71.67 $42.8 $7.9 32.50% 28.18% 7.9
Company (AMEX)
CPHI
China Pharma $2.67 $115.58 $61.7 $20.3 13.46% 21.05% 5.6
(AMEX)
Simcere SCR
$8.13 $447.27 $270.9 $17.5 -65.89% 6.24% 22.0
Pharmaceuticals (NYSE)
Average 12.4% 24.3% 6.4
24
25. Investment Summary
Attractive industry dynamics supports long-term growth
Strong R&D capability ensures high margin pipelines
Competitive advantage with solid portfolio of proprietary
SFDA approved therapeutics
Expanding multi-channel distribution network to increase
market penetration
Established quality brand name
Fragmented industry creates
opportunities for acquisitions
25
26. Contact Information
Company: Investor Relations:
Ren Hu Elite IR
VP of Finance John Marco
Weikang Bio-Technology Group Phone: (310) 819-2948
Phone: (201) 887 0415 Email: john.marco@elite-ir.com
Email: arenhu@gmail.com
Legal Counsel: Auditor:
The Crone Law Group Ahmed Mohidin, Partner
Wayne Chiang Goldman Parks Kurland Mohidin, LLP
101 Montgomery Street 16133 Ventura Blvd.
Suite 1950, Suite 880
San Francisco, CA 94104 Encino, CA 91436
Phone: (415) 955-8900 Phone: (818) 784-9000
Email: wchiang@cronelaw.com Email: ahmed@gpkmllp.com
26